Real-life experiences with bulevirtide for the treatment of hepatitis delta-48 weeks data from a German centre.
Caroline ZöllnerJörg HofmannKatrin LutzFrank TackeMünevver DemirPublished in: Liver international : official journal of the International Association for the Study of the Liver (2022)
In July 2020, the entry inhibitor bulevirtide was approved in the European Union for the treatment of chronic hepatitis delta virus (HDV) infection. We describe the first 48 weeks of bulevirtide therapy in eight patients (n = 7 male, n = 1 female; n = 3 compensated cirrhosis) treated at our centre. Median ALT values declined from 82 to 34 U/L after 48 weeks. Median HDV RNA dropped from 13 380 000 to 3135 copies/ml. One patient showed no significant response and was discontinued at week 16. Overall, we observed a favourable safety profile and a marked biochemical and virological response in the majority of our patients.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- stem cells
- randomized controlled trial
- mesenchymal stem cells
- mental health
- patient reported outcomes
- hiv infected
- electronic health record
- clinical trial
- case report
- bone marrow
- gestational age
- big data
- combination therapy
- nucleic acid
- preterm birth